Keywords: merck, kgaa, licenses, glenmark, dpp-4, drug, darmstadt
Merck KGaA licenses Glenmark's DPP-4 drug
Article | 12 March 2007
Darmstadt, Germany-based Merck KGaA has licensed Indian drugmaker Glenmark Pharmaceuticals' GRC 8200. The novel dipeptidyl peptidase-4 inhibitor is a potential treatment ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
